Ophthalmology

Experts discuss the results of Protocol T study comparing anti-vascular endothelial growth factor (Anti-VEGF) agents for the treatment of diabetic macular edema (DME).

Presented at ASRS 2023, results from the GALE extension study showed crossover to pegcetacoplan treatment from sham stabilized photoreceptor degeneration over 6 months.

A post hoc analysis of YOSEMITE/RHINE presented at ASRS 2023 suggests faricimab is linked to the faster absence of retinal fluid and fewer injections versus aflibercept in eyes with DME.

Presented at ASRS 2023, an analysis of the Portal trial suggests the efficacy and safety of PDS with ranibizumab was maintained over 5 years in patients with nAMD.

Reports of a half-dozen confirmed cases of the rare vision-threatening condition has spurred conversation around the first-in-class geographic atrophy drug.

Presented at ASRS 2023, results suggest the potential proof-of-concept for the safety, tolerability, and efficacy of UBX1325 in patients with DME.

Dr. Hahn discusses an anchored matching-adjusted indirect comparison in patients with geographic atrophy, suggesting a greater reduction in observed lesion growth with monthly pegcetacoplan versus avacincaptad pegol.

Presented at ASRS 2023, pegcetacoplan injection showed increasing treatment effects over 30 months for patients with geographic atrophy, with a consistent safety profile to previous phase 3 data.

Late-breaking findings at ASRS 2023 suggest daily home OCT imaging is sufficient for remotely monitoring fluid among patients with treatment-naïve nAMD.

Presented at ASRS 2023, the results showed clinically meaningful reductions in anti-VEGF treatment burden at all dose levels of intravitreal 4D-150 in patients with a high anti-VEGF need.

At ASRS 2023, results from the MOSAIC study indicate the substantial burden of geographic atrophy on patients and their caregivers across the United States and Canada.

Presented at ASRS 2023, study data suggest aflibercept 8 mg provided greater therapeutic benefit, an extended injection interval, and equivalent safety versus aflibercept 2 mg in eyes with nAMD.

However, the meta-analysis of patients treated with ranibizumab suggests a similar proportion of patients achieved DME resolution, regardless of baseline DR severity, by month 24.

Experts discusses the unique challenges managing the care of patients with diabetic macular edema (DME).

Experts discuss prospective therapies and improved outcome targets for patients with neovascular age-related macular degeneration (nAMD).

Granted to Tarsus Pharmaceuticals, the approval of lotilaner ophthalmic solution 0.25% marks the first-and-only FDA-approved therapeutic for Demodex blepharitis, a common eyelid disease.

A combination of baseline factors, early BCVA, and morphologic responses at 3 months only moderately predicted long-term BCVA responses in eyes with nAMD.

Low vision rehabilitation was associated with statistically significant increases in the overall composite score of a vision-related quality of life scale.

Experts discuss their experience using the treat and extend strategy with aflibercept and their clinical advice when administering treatment.

Experts discuss the long-term efficacy and safety of aflibercept in the treatment of neovascular age-related macular degeneration (nAMD).

Based on objective assessments of visual function with habitual correction, both distance and near visual impairment, and contrast sensitivity impairment, were associated with a higher dementia prevalence.

The AI chatbot, ChatGPT-4, responded correctly to 84% of multiple-choice practice questions on the OphthoQuestions trial, compared to 58% in February 2023.

Real-world evidence suggests the rapid reduction of HbA1c is not associated with early worsening in subjects with T2D with mild or moderate nonproliferative DR.

Use of atropine, 0.01%, eye drops did not slow myopia progression or axial elongation better than placebo in children aged 5 - 12 years.

Experts discuss the comparison of age-related macular degeneration treatments trials (CATT) and how today’s retina specialists can apply the results in their daily practice.

Experts discuss how they define suboptimal responders to anti-vascular endothelial growth factor (Anti-VEGF) treatment and how they manage the care of those patients.

A systematic review and meta-analysis revealed that combination therapy was associated with superior anatomical outcomes in all but 1 included study.

The latest episode of New Insight with Veeral Sheth, MD features an insightful conversation with David Eichenbaum, MD on his goals in mentoring the next generation of retina specialists, sharing anecdotes about his own journey in ophthalmology.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our June 2023 month-in-review features updates to the pipeline, diabetic eye disease news from ADA 2023, and promising data on the use of artificial intelligence.

Experts offer clinical advice on identifying and managing suboptimal responders on anti-vascular endothelial growth factor (Anti-VEGF) treatment.